secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001140361-25-008178
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis licenses sapablursen to Ono for $280M upfront, up to $660M milestones and mid-teen royalties
--------------------------------------------------------------------------------

- $280M upfront payment; up to $660M in development, regulatory and sales milestones.
- Sapablursen is an investigational RNA-targeted medicine for polycythemia vera; has FDA orphan drug and Fast Track designations.
- Ono receives exclusive global rights; Ionis completes Phase 2 IMPRSSION study, Ono handles subsequent development and commercialization.
- Ionis eligible for royalties in the mid-teen percentage range on annual net sales of sapablursen.
- Transaction subject to Hart-Scott-Rodino Antitrust Improvements Act (HSR) review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125008178/0001140361-25-008178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125008178/ef20045255_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-008178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer